Birthing Centre wins a Prix Hippocrate
18 October 2024
4 October 2024
As of November 1, 2024, a new medication called nirsevimab will be available in Quebec to prevent respiratory syncytial virus (RSV).
RSV is a common, highly contagious respiratory virus, infecting nearly all children by two years of age.
It is the most common cause of bronchiolitis and pneumonia in children less than one year of age.
A Quebec-based study found RSV was the most common virus (63.6 per cent) in children hospitalized for acute respiratory infection, with higher severity in children born prematurely and babies under six months of age (Papenburg et al, 2012).
Nirsevimab will be available at CLSCs and local points of service for:
How is it given?
Nirsevimab is administered at the start/during RSV season as an intramuscular injection, usually in the thigh muscle.
Where will it be given?
Don’t hesitate to book an appointment for your child!
Birthing Centre wins a Prix Hippocrate
18 October 2024
The MCH shines on the international stage!
11 October 2024
Promising results for the Smart Hospital Project
11 October 2024
Does your child chew his hair or bite his nails?
7 October 2024
4 October 2024
A competition to improve emergency medicine
4 October 2024
One year of success for the RVH Breastfeeding Clinic!
2 October 2024
A career dedicated to health equity
10 September 2024